Hikma receives FDA approval for Methylprednisolone Sodium Succinate Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Methylprednisolone Sodium Succinate Injection USP, 500mg/vial and 1 gm/vial has been approved by the U.S. Food and Drug Administration (“FDA”).

Press Release Product 9 March 2016

Methylprednisolone Sodium Succinate Injection is a corticosteroid hormone indicated to treat conditions such as arthritis, blood disorders, skin and kidney diseases and other system disorders. According to IMS Health, sales of Methylprednisolone Sodium Succinate Injection in the US market were approximately $123.5 million for the 12 months ending January 2016.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.